Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Am J Emerg Med ; 48: 357-360, 2021 10.
Article in English | MEDLINE | ID: covidwho-1051416

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases. It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher risk of serious complications and death from COVID-19. Some cancer treatments such as CAR T cell therapy can produce a cytokine storm, which is also a hallmark of severe COVID-19. Therefore, patients receiving CAR T cells are at higher risk if they become infected with COVID-19, and could be treated with anti-cytokine approaches.


Subject(s)
COVID-19/physiopathology , Neoplasms/physiopathology , COVID-19/complications , COVID-19/immunology , Cytokine Release Syndrome/immunology , Disease Susceptibility , Hematologic Neoplasms/complications , Hematologic Neoplasms/immunology , Hematologic Neoplasms/physiopathology , Hematologic Neoplasms/therapy , Humans , Immunocompromised Host , Immunotherapy, Adoptive/adverse effects , Lung Neoplasms/complications , Lung Neoplasms/immunology , Lung Neoplasms/physiopathology , Lung Neoplasms/therapy , Neoplasms/complications , Neoplasms/immunology , Neoplasms/therapy , Receptors, Chimeric Antigen , SARS-CoV-2 , Severity of Illness Index , T-Lymphocytes/immunology
SELECTION OF CITATIONS
SEARCH DETAIL